Tissue Regenix Ltd - John Samuel, former CEO of Mölnlycke Health Care Group, appointed Chairman

18 Apr 2008

John Samuel, former CEO of Mölnlycke Health Care Group (MHCG), third in the European advanced wound care market and # 1 European single use-surgical products provider, has joined Tissue Regenix, a University of Leeds spin off company developing revolutionary products in tissue regeneration, as Chairman.

Tissue Regenix, which recently received a £3M investment package from a syndicate of
investors, is delighted to have the new Chairman on board. John Fisher, a founder and Director of Tissue Regenix, commented: "John's experience and knowledge of the healthcare sector is phenomenal. He has led one of the world's largest health care groups and delivered outstanding returns for investors. We are very pleased that he has chosen to join Tissue Regenix and see this as a real coup for the company.”

John Samuel, Chairman of Tissue Regenix, commented: "I am delighted to be joining Tissue Regenix at this stage of the company’s development. I believe that the company’s technology could offer ground breaking advances in the field of tissue regeneration and look forward to working with the team to deliver on that potential.”

MHCG was sold last year to Investor AB and Morgan Stanley Principal Investments (MSPI) for EUR 2.85 bn.

Notes for Editors

About John Samuel

John Samuel was formerly CEO of the Mölnlycke Health Care Group (MHCG), one of the world’s leading providers of single-use surgical and wound care products and services to the healthcare sector. MHCG was created from the successful integration of 3 companies (Regent, Medlock and Mölnlycke) and was acquired by Investor AB in March 2007 for approximately €2.85bn. Previous to this John was involved with several companies including AIM listed Purewafer plc and has held a number of senior finance
positions in industry, including Ellis & Everard plc andWhessoe plc

About Tissue Regenix Ltd

Tissue Regenix Limited was formed in May 2006. The underpinning science was developed over the last decade by Professors John Fisher and Eileen Ingham as a result of their research and expertise in biocompatibility, immunocompatibility and functional tissue re-engineering.

Tissue Regenix products, which are produced from animal tissues, have an acellular architectural structure that is comparable to human tissue, and are therefore not perceived as foreign bodies by the host tissue. This lack of rejection allows the Tissue Regenix products to work by supporting fibroblast and smooth muscle cell infiltration, reendothelialisation and revascularisation, so that it gradually becomes incorporated into the surrounding tissue, repairing, replacing or providing strength and support to the tissue defect.